氩氦刀联合肝动脉化疗栓塞术治疗原发性肝癌的临床研究

目的：观察氩氦刀联合肝动脉化疗栓塞术治疗原发性肝癌的疗效。方法：40例原发性肝癌病人,根据病人情况选择TACE术和氩氦刀冷冻消融术治疗的先后顺序。1月后复查血清AFP、肝脏CT增强扫描及肝动脉造影（DSA）检查。随诊12个月。结果：治疗前AFP〉400ng/ml,治疗后下降〉50%者83.9%（26/31）;肝脏CT增强扫描及DSA造影提示：肿瘤完全坏死50.0%（20/40）;不完全坏死27.5%（11/40）;部分坏死22.5%（8/40）。6个月、12个月生存率分别为91.0%和76%。治疗中、 治疗后未发生严重并发症。结论：氩氦刀联合肝动脉化疗栓塞术治疗原发性肝癌疗效确切，不良作用少。

Effect of cryotherapy by employing Argon/Helium subsequently combined with TACE on primary hepatic carcinoma

Objective：To investigate the effect of cryotherapy of employing Argon/Helium subsequently combined with TACE for primary hepatic carcinoma.Methods：Forty cases with primary hepatic carcinoma received cryotherapy of employing Argon/Helium subsequently combined with TACE.One month after the combined treatment,AFP（alpha-fetoprotein） and liver CECT（contrast enhancement computed tomography） and DSA were examined.The follow-up time was 12 months.Results：In 83.9% of patients with AFP level up to 400ng/ml,AFP value decreased more than 50%.Complete tumor necrosis was observed by liver CECT and DSA in 50.0%;incomplete necrosis in 27.5%;part necrosis in 22.5%.The 6-month and 12-month survival rates were 91.0% and 76.0% respectively without severe complications in the treatment.Conclusion：Subsequent combination of cryotherapy of employing Argon/Helium with TACE is an effective and safe therapy for primary hepatic carcinoma.